SAN DIEGO, July 29 CA-Vical-Conf-Call
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the company will report financial results
for the three months and six months ended June 30, 2008, before the opening of
trading on Tuesday, August 5, and conduct a conference call and webcast to
discuss the financial results and provide a company update at noon Eastern
Time on Tuesday, August 5. The call is open on a listen-only basis to any
interested parties. The company will provide details on independent and
partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before
the scheduled call to (888) 600-4883, or (913) 312-6683 for international
participants, and reference confirmation code 4962317. A replay of the call
will be available for 48 hours beginning about two hours after the call. To
listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international
participants, and enter replay passcode 4962317. The call also will be
available live and archived through the events page at http://www.vical.com.
Invited analysts and institutional investors may ask questions during the
conference call. Others may submit questions before the call by e-mail
addressed to info@vical.com or by fax to (858) 646-1150. Submitted questions
will be screened for appropriateness and general interest. Selected questions
received with sufficient notice before the call will be answered as time
permits at the end of the call. For further information, contact Vical's
Investor Relations department by phone at (858) 646-1127 or by e-mail at
info@vical.com.
About Vical
Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of serious
or life-threatening diseases. Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor. The
company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major
pharmaceutical companies and biotechnology companies that give it access to
complementary technologies or greater resources. These strategic partnerships
provide the company with mutually beneficial opportunities to expand its
product pipeline and address significant unmet medical needs. Additional
information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ materially from
those projected. Forward-looking statements include statements about the
company's focus, collaborative partners, product candidates, and developmental
status. Risks and uncertainties include whether any product candidates will be
shown to be safe and efficacious in clinical trials, the timing of clinical
trials, whether Vical or its collaborative partners will seek or gain approval
to market any product candidates, the dependence of the company on its
collaborative partners, and additional risks set forth in the company's
filings with the Securities and Exchange Commission. These forward-looking
statements represent the company's judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these
forward-looking statements.
Contact: Alan R. Engbring
(858) 646-1127
Website: http://www.vical.com
SOURCE Vical Incorporated
